Our findings demonstrate that liver-specific activation of AMPK is sufficient to protect against hepatic triglyceride accumulation, a hallmark of non-alcoholic fatty liver disease (NAFLD). This evidence concerns the gene PRKAA2 and metabolic dysfunction-associated steatotic liver disease.